Nasdaq Sends Delisting Notice to Estrella Immunopharma Over Sub-$1.00 Bid Price

summarizeSummary

Estrella Immunopharma received a Nasdaq delisting notice after its stock traded below $1.00 for 30 consecutive days. The company has until February 16, 2027 to regain compliance, potentially via a reverse stock split.

check_boxKey Events · Legal and Risk Events · ESLA

• Nasdaq Delisting Notice Received

  On August 17, 2026, Nasdaq notified Estrella Immunopharma that its common stock closed below $1.00 for 30 consecutive business days (July 6 – August 14, 2026), violating Listing Rule 5550(a)(2).

• 180-Day Compliance Period

  The company has until February 16, 2027 to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

• Reverse Stock Split Likely

  To regain compliance, the company may implement a reverse stock split, which must be completed no later than ten business days before the compliance deadline.

• Financial Distress Compounds Risk

  The delisting notice follows the company's Q2 10-Q disclosing going concern doubt with only $0.1M cash against $9.3M current liabilities, heightening the risk of delisting.

auto_awesomeAnalysis · ESLA · Life Sciences

A formal notice from Nasdaq has put Estrella Immunopharma on the clock: its stock has traded below the $1.00 minimum bid requirement for 30 consecutive business days. The company now has 180 days, until February 16, 2027, to regain compliance, likely through a reverse stock split. This development compounds an already precarious situation—a going-concern warning and just $0.1M in cash disclosed in the recent 10-Q—making the delisting threat a critical risk to the company's survival.